CureVac participating in broad UK trial evaluating different COVID-19 vaccines as potential boosters at least three months following full primary vaccination First preclinical data of second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates faster onset of antibody production and high variant cross-neutralization A Covid-19 vaccine being developed by Germany’s CureVac was shown to be just 47 percent effective in an interim analysis of its late-stage trial, the company said Wednesday. A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants. Poor interim trial results for Germany’s CureVac jab. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said. CureVac initiates a Phase 2a clinical trial of its COVID-19 vaccine candidate in Peru and Panama. CureVac started its Phase 2a Clinical Trial with CVnCoV at the end of September 2020. The setback for CureVac comes on top of delays as its late-stage trial was slowed by the wait for enough participants to catch Covid. The aim is to establish the optimal dose of the Covid-19 vaccine. "We recognize that demonstrating high efficacy in this unprecedented broad diversity of variance is quite challenging.” Still, CureVac said it will continue to analyze data from the trial and this may affect the final outcome. Geneva, June 18 (Reuters) - The World Health Organization's chief scientist said on Friday that results from the CureVac COVID-19 vaccine's initial trial were disappointing. CureVac stock plunged 50% in extended trading Wednesday after the German biopharmaceutical company released preliminary efficacy results for its Covid-19 vaccine candidate. German COVID-19 vaccine developer Curevac, which is banking on a technology that has allowed rivals BioNTech and Moderna to lead the development race, on Thursday said it … Shares of the German biopharmaceutical company, CureVac (CVAC) plunged about 45% in early trading after the company released disappointing data from its second interim trials of the COVID-19 vaccine. While both Pfizer-BioNTech and Moderna delivered late-stage trial results in November, CureVac didn’t vaccinate its first volunteer in late-stage trials until December. The Jefferies analyst said CureVac's readout was in stark contrast with results announced by Novavax this week, showing that its experimental COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a U.S.-based clinical trial. CureVac announced late Wednesday that the vaccine had shown an efficacy of 47% against COVID-19 of any severity, according to a partial review of data from its trial … The vaccine has shown a 47% efficacy rate, which “did not meet pre-specified statistical success criteria,” the company said in … CureVac began development of its mRNA-based COVID-19 vaccine candidate in January 2020. They expect to enroll more than 36,000 people. CureVac started its Phase 2a Clinical Trial with CVnCoV at the end of September 2020. The dose-confirmation study has been conducted in Peru and Panama and enrolled a total of 670 participants in two distinct groups: older adults ages 61 and above, and younger participants 18 to 60 years old. Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively. The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming … In a bet on CureVac's technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial. The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming … Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said. By Ludwig Burger. CureVac announced late Wednesday that the vaccine had shown an efficacy of 47% against COVID-19 of any severity, according to a partial review of data from its trial … The final analysis for the trials requires a minimum of 80 additional cases. CureVac suffers 50% pre-market plunge after trails reveal its COVID-19 vaccine revealed is only 47% effective against combatting the virus. The CV7202 clinical trial is based on CureVac’s naturally optimized mRNA technology using a latest generation lipid nanoparticle (LNP). CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates ... at one and six month post second dose * CureVac participating in broad UK trial … In a 2b/3 clinical trial, CureVac said its COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. BERLIN, Germany – A COVID-19 vaccine being developed by Germany’s CureVac was shown to be just 47 percent effective in an interim analysis of its late-stage trial, the company said Wednesday. CureVac's COVID-19 vaccine failed in preliminary trial results. Still, CureVac said it will continue to analyze data from the trial and this may affect the final outcome. CureVac's COVID-19 vaccine failed in preliminary trial results. CureVac plans to move seamlessly into the phase 3 clinical trial if the data support the larger study. The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming … The study will enroll 36,500 participants in Europe and … BioNTech, like CureVac a German company and a pioneer of mRNA research, shot to fame and saw its value soar after its own vaccine candidate showed high efficacy in late-stage trials … In November 2020, CureVac reported results of a Phase I-II clinical trial that CVnCoV (active ingredient zorecimeran) was well-tolerated, safe, and produced a robust immune response. -German biotech CureVac NV said on Wednesday its COVID -19 vaccine was only 47% effective in a late-stage trial… Credit: MasterTux from Pixabay. On November 2, the company had also disclosed some clinical data. CureVac blames the unprecedented context of at least 13 variants circulating within the study population subset assessed for the disappointing result of its Covid-19 vaccine. CureVac shares fell by as much as 52% on Thursday after the German biotech's COVID-19 vaccine proved only 47% effective in an initial trial, denting investor confidence in … June 16, 2021 A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants. The European Union began a rolling review in February, intended to speed up approval if the Phase 3 trial delivers positive results. The results of the 40,000-person trial, announced by … The results strengthen the impression that the vaccine triggers … "Due to the Defense Production Act we are not getting certain goods out of the USA," CureVac Chief Executive Franz-Werner Haas told weekly Der Spiegel. CureVac receives a grant of up to 252 million euros from the German Federal Ministry of Education and Research to further its COVID-19 vaccine development and expand its production capacity. The interim results from the late-stage testing are below the minimum threshold of 50 per cent efficacy set by the World Health Organisation. The Jefferies analyst said CureVac’s readout was in stark contrast with results announced by Novavax this week, showing that its experimental COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a U.S.-based clinical trial. CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, … German biotech CureVac NV on June 16 announced that its COVID-19 vaccine was only 47 per cent effective in a late-stage trial. June 16, 2021 A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants. CureVac Shares Plunge Premarket on Disappointing Covid-19 Vaccine Trial Vaccine was 47% effective in an analysis of a trial, says the company, which attributed the … CureVac plans to pool data from the phase 2b and 3 portions of the clinical trial. “The results are sobering," said chief executive Franz-Werner Haas. About the CV7202 Clinical Trial. “The goal is to have interim results in the first quarter of 2021, which will form the basis - provided the data is good, and we are hopeful - for filing a so-called rolling submission with regulators,” Chief Executive Franz-Werner Haas told Reuters on Monday. CureVac announced late Wednesday that the vaccine had shown an efficacy of 47% against COVID-19 of any severity, according to a partial review of data from its trial … Wall Street analysts are taking a far more pessimistic view of CureVac as the stock tumbles after the German biotech reported disappointing results from a late-stage trial … Geneva (Reuters) – The World Health Organization’s chief scientist said on Friday that results from the CureVac COVID-19 vaccine’s initial trial were disappointing. Two primary study centers have already been identified and are in preparation for clinical trials. The European Commission offers up to €80 million of financial support to CureVac to scale up the development and production of a vaccine against the coronavirus in Europe. Germany-produced COVID-19 candidate vaccine CureVac has produced disappointing results in late-stage trials, where it was shown to be 47 percent effective against the disease. The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected until the end of June. Germany's CureVac, which is gearing up to publish results of a key COVID-19 vaccine trial, said U.S. export restrictions on key materials are making it impossible to predict its short-term supply ramp-up in Europe. Participants with a significant acute or chronic medical or psychiatric illness that, in the opinion of the investigator, precludes trial participation (e.g., may increase the risk of trial participation, render the participant unable to meet the requirements of the trial, or may interfere with the participant's trial evaluations). The setback for CureVac comes on top of delays as its late-stage trial was slowed by the wait for enough participants to catch COVID. “The results are sobering," said chief executive Franz-Werner Haas. The German company CureVac delivered disappointing preliminary results on Wednesday from a clinical trial of its Covid-19 vaccine, dimming … CureVac's COVID-19 vaccine failed in preliminary trial results. by Agence-France-Presse. Poor interim trial results for Germany's CureVac jab Wednesday, June 16, 2021 BERLIN, Germany (AFP) — A COVID-19 vaccine being developed by Germany's CureVac was shown to be just 47 per cent effective in an interim analysis of its late-stage trial, the company said Wednesday. The German government, which invested 300 million euros ($358 million) in CureVac last year, said the disappointing results won’t affect its initial vaccine campaign. The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected until the end of June. Shares of CureVac … A closely watched coronavirus vaccine invented by the German company CureVac was just 47% effective in a large trial at its interim analysis, a disappointing result that may highlight the challenge posed by virus variants. CureVac has presented more clinical data on its COVID-19 vaccine candidate. CureVac's COVID-19 vaccine failed in preliminary trial results. CureVac said the study was hampered by the broad range of variants found among the COVID-19 cases reviewed in the trial and that final results may still change. Poor interim trial results for Germany's CureVac jab. CureVac CVAC -3.47% NV said Wednesday its experimental Covid-19 vaccine was 47% effective against the disease in an interim analysis of a large clinical trial, a … German biotech firm CureVac’ vaccine proved only 47% effective in an initial trial … Early September 2020. Results were based on clinical trials conducted in Latin America and Europe on about 40,000 volunteers. CureVac stock plunged 50% in extended trading Wednesday after the German biopharmaceutical company released preliminary efficacy results for its Covid-19 vaccine candidate. The company has blamed the results on the "unprecedented context of at least 13 variants circulating within the study population subset assessed." The company has blamed the results on the "unprecedented context of at least 13 variants circulating within the study population subset assessed." CureVac suffers 50% pre-market plunge after trails reveal its COVID-19 vaccine revealed is only 47% effective against combatting the virus. CureVac said that the study was hampered by the broad range of variants found among the COVID-19 cases reviewed in the trial and that final results may still change. A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was due largely to the difficulties posed by new variants. Published June 17, 2021, 6:29 AM. The co-primary endpoints of the trial cover prevention of all COVID-19 cases and just severe cases. The compound is an optimized, non-chemically modified mRNA, encoding the pre-fusion stabilized full-length spike protein of the SARS-CoV-2 virus. The results from a trial with 40,000 participants have caused CureVac shares in Frankfurt and New York to fall more than 50 per cent, erasing more than £5billion from the company’s market value. Preliminary results from second and third-phase trials on 40,000 subjects in 10 countries of Europe and Latin America show that CureVac’s jab “did not meet pre-specified statistical success criteria,” the company announced on Wednesday. CureVac lost more than half its value after its COVID-19 vaccine jab showed 47% effectiveness. Poor interim trial results for Germany’s CureVac jab. CureVac said that the study was hampered by the broad range of variants found among the COVID-19 cases reviewed in the trial and that final results may still change. A coronavirus vaccine manufactured by German company CureVac was only 47 percent effective in interim results, the company announced Wednesday, a major setback that was … The phase 3 study will recruit 32,500 subjects. A Covid-19 vaccine being developed by Germany’s CureVac was shown to be just 47 percent effective in an interim analysis of its late-stage trial, the company said Wednesday. The setback for CureVac comes on top of delays as its late-stage trial was slowed by the wait for enough participants to catch Covid. CureVac has secured approval from the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) for Phase I clinical trial of its Covid-19 vaccine candidate, named CVnCoV. Meanwhile, CureVac is also working on a second-generation vaccine, aiming to start trials this fall. Shares of Curevac rose 10% in premarket trading on Friday. The result of the current data is they plan to move ahead with Phase II and Phase III trials with the 12-microgram dose. Clinical trial progress. WHO chief scientist disappointed by CureVac trial. CureVac attributed the underwhelming results to strains of the virus circulating in 10 countries across Latin America and Europe, where its trials were carried out. Shares in CureVac plummeted on Thursday after the German biotech company said that interim trial results showed its experimental Covid-19 vaccine was … Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial … Germany-produced COVID-19 candidate vaccine CureVac has produced disappointing results in late-stage trials, where it was shown to be 47 percent effective against the disease. "We recognize that demonstrating high efficacy in this unprecedented broad diversity of variance is quite challenging.” Still, CureVac said it will continue to analyze data from the trial and this may affect the final outcome. In February 2021 CureVac and the British pharmaceutical company GlaxoSmithKline (GSK) agreed to jointly develop next-generation multi-valent mRNA vaccines against COVID-19. The development of new vaccine candidates is strengthened by a partnership with the UK Government and its Vaccines Taskforce, which CureVac also entered in February 2021. The European Union began a rolling review in February, intended to speed up approval if the Phase 3 trial delivers positive results. Still, CureVac said it will continue to analyze data from the trial and this may affect the final outcome. Germany's CureVac expects initial results from a late-stage trial of its COVID-19 vaccine early in the second quarter because the biotech group aims to have read-outs for specific variants. Tubingen-based pharmaceutical firm CureVac revealed the preliminary results of the late-stage trial of its CVnCoV coronavirus vaccine on Wednesday. CureVac has begun a phase 2b/3 clinical trial of its COVID-19 vaccine candidate CVnCoV. CureVac shares fell by as much as 52% on Thursday after the German biotech's COVID-19 vaccine proved only 47% effective in an initial trial, denting investor confidence in … Text size Aa Aa. The spokesperson said that the results of the next data update would be released to the public and the EMA as soon as it was available. The dose-confirmation study has been conducted in Peru and Panama and enrolled a total of 670 participants in two distinct groups: older adults ages 61 and … The phase 1, dose-escalation, open-label clinical study in healthy adult volunteers is … CureVac stock climbed 8.28% in premarket trading at the news of the Phase I data. CureVac said that the study was hampered by the broad range of variants found among the COVID-19 cases reviewed in the trial and that final results may still change.